Loading…
← CockpitCompetitor Analysis › 300049.SZ Inner Mongolia Furui Medical Science Co., Ltd. Class AOpen in the cockpit ↗

Inner Mongolia Furui Medical Science Co., Ltd. Class A300049.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Liver-disease company: owns FibroScan liver-stiffness scanners through French unit Echosens and sells the liver-fibrosis drug Fufang Biejia Ruangan.

Momentum neutral 52
Mkt cap
$1.45B
US dollars, full cap
Free float
93%
of shares outstanding
$/day
$62.7M
20-day average traded
Fwd P/E
41.9×
forward earnings
ROIC−WACC
+9.6 pp
WACC 5.0%
Hurdle
-12 pp
Req g minus delivered
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥39.00
1D-3.3%
1W-13.1%
1M-1.8%
3M-15.9%
6M-31.5%
YTD-44.6%
1Y-45.7%
ATR %6.8%
52w lowhigh55.1% off high

What Inner Mongolia Furui Medical Science does

Liver-disease company: owns FibroScan liver-stiffness scanners through French unit Echosens and sells the liver-fibrosis drug Fufang Biejia Ruangan.

Pairs a diagnostic with a treatment in one disease area: FibroScan scanners, made by its French unit Echosens, are sold to hospitals and clinics for non-invasive liver testing, and a protected traditional Chinese medicine for liver fibrosis is sold through pharmaceutical distributors. Echosens sells in China and overseas and holds the core elastography patents.

Products and services

  • FibroScan liver-stiffness scanners (Echosens)
  • Compound Biejia Ruangan tablets (liver-fibrosis TCM)

Customers

  • Hospitals and liver clinics
  • Pharmaceutical distributors

Where it sits in the supply chain

  • Health care
  • Diagnostics and drugs
  • Liver-disease diagnosis and treatment

What could go right

  • Fatty-liver screening demand
  • FibroScan expansion in China and overseas

What could go wrong

  • Dependence on one device and one drug
  • Reimbursement and pricing pressure

Moat: narrow (IP / patents, installed base). Pioneer of transient elastography with a large installed base; the drug is a nationally protected Chinese patent medicine.

Headquarters: Beijing, China · Founded: 2001 · Employees: 964

Named competitors

Inner Mongolia Furui Medical Science at a glance

Size Inner Mongolia Furui Medical Science (300049.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.45B, the 1557th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥39.00 on 18 Nov 2026.

Performance Over six months the shares fell 31.5%, against -1.8% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.

Growth Revenue grew 11.3% over the last twelve months (peer median +13.3%); the operating margin is 25.5% (peer median 6.8%).

Valuation It trades at 41.9× forward earnings against a peer median of 25.1× (4th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -12 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 9.6 points above its cost of capital (5.0% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 100300049.SZ 69
Six months, rebased to 100: Inner Mongolia Furui Medical Science against the median of its 20 peers (local-currency closes).

Inner Mongolia Furui Medical Science financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.64BCN¥1.59BCN¥1.35BCN¥1.14BCN¥998M
Revenue growth—+18%+18%+15%—
Gross profitCN¥1.24BCN¥1.09BCN¥931MCN¥813MCN¥698M
EBITDAn/aCN¥505MCN¥380MCN¥335MCN¥255M
Net incomeCN¥176MCN¥154MCN¥113MCN¥102MCN¥97.9M
Free cash flowCN¥247MCN¥165MCN¥5.12MCN¥121MCN¥105M
Capital expenditureCN¥164MCN¥189MCN¥219MCN¥189MCN¥90.8M
Total debtCN¥254MCN¥137MCN¥83.4MCN¥59.3MCN¥55.7M

Quarterly statements and history in the cockpit →

Inner Mongolia Furui Medical Science competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-20%0%+20%300298PRCTELNCNMD6880166849ENOVVITR6885313005953010876881986887583006336699BFLYSTAA8086INSPKMTS300049.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Inner Mongolia Furui Medical Science is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%20×40×300298ELNCNMD6880166849ENOVVITR6885313010876881986887583006336699STAAINSP300049.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Inner Mongolia Furui Medical Science is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%300298ELNCNMD6880166849ENOVVITR3005953010876881986699STAAINSP300049.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Inner Mongolia Furui Medical Science is the large dot.

Inner Mongolia Furui Medical Science competitors and peer comparison

Head to head with its named competitors (300049.SZ vs 300760.SZ vs SHL.DE vs GEHC)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Inner Mongolia Furui Medical Science 300049.SZ$1.45B-31%+11%25%41.9×2.9%
Shenzhen Mindray Bio-Medical Electronics 300760.SZ$33.6B+15%+5%28%27.3×1.0%
Siemens Healthineers SHL.DE$53.7B+27%+1%14%18.9×9.6%
GE HealthCare GEHC$37.8B+30%+7%14%15.6×5.0%

How Inner Mongolia Furui Medical Science compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Inner Mongolia Furui Medical Science against its 20 peers (data as of 18 Nov 2026)
Measure300049.SZPeer medianRank in peer set
1-month return-1.8%-0.1%9th lowest of 21
6-month return-31.5%-1.8%3rd lowest of 21
Distance from 52-week high-55.1%-26.7%3rd lowest of 21
Revenue growth (TTM)+11.3%+13.3%11th highest of 21
Operating margin25.5%6.8%5th highest of 21
Forward P/E41.9×25.1×4th most expensive of 18
Growth the price implies (Req g, 7 yrs)2.9%18.4%3rd least demanding of 15
Growth delivered (Del g)+14.6%+17.4%7th lowest of 15
Hurdle (Req g minus delivered)-11.7 pp-3.8 pp3rd least demanding of 15
ROIC minus cost of capital+9.6 pp-1.1 pp5th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Inner Mongolia Furui Medical Science 300049.SZChina$1.45B-31%+11%25%41.9×2.9%+14.6%
Sinocare 300298.SZChina$1.45B+4%+7%6%21.5×9.5%+18.3%
PROCEPT BioRobotics PRCTUnited States$1.45B-10%+17%-34%n/an/an/a
El.En ELN.MIItaly$1.46B+11%+3%15%22.0×10.7%+7.7%
CONMED CNMDUnited States$1.43B+30%+2%2%10.4×31.6%+9.8%
Shanghai MicroPort Endovascular MedTech 688016.SSChina$1.55B-19%+16%44%16.4×2.7%+23.4%
Nihon Kohden 6849.TJapan$1.55B+3%0%7%18.8×-3.5%+3.3%
Enovis ENOVUnited States$1.56B+2%+3%4%7.6×20.0%-6.0%
Vitrolife VITR.STSweden$1.57B+13%-2%19%27.0×22.2%+22.5%
Wuxi Unicomp Technology 688531.SSChina$1.58B-49%+53%12%35.8×n/an/a
Ovctek China 300595.SZChina$1.33B-25%0%28%19.4×8.3%+16.5%
Cofoe Medical Technology 301087.SZChina$1.60B-6%+33%10%25.1×11.2%+7.4%
Beijing Balance Medical Technology 688198.SSChina$1.31B-32%+10%28%41.5×20.7%+27.6%
Suzhou Sepax Technologies 688758.SSChina$1.31B+8%+28%40%46.0×22.8%+23.6%
Sonoscape Medical 300633.SZChina$1.31B-10%+18%4%34.7×n/an/a
Angelalign Technology 6699.HKHong Kong$1.62B-8%+84%9%52.5×16.7%+25.8%
Butterfly Network BFLYUnited States$1.63B+38%+39%-36%n/an/an/a
STAAR Surgical STAAUnited States$1.27B-23%+42%7%46.9×35.1%+7.9%
NIPRO 8086.TJapan$1.68B-11%+5%5%15.8×n/an/a
Inspire Medical Systems INSPUnited States$1.68B+32%0%2%41.3×28.7%+51.2%
Kestra Medical Technologies KMTSUnited States$1.69B+36%+61%-134%n/an/an/a

Questions

Who are Inner Mongolia Furui Medical Science's main competitors?
Named competitors: Mindray (300760.SZ), Siemens Healthineers (SHL.DE), GE HealthCare (GEHC). The cockpit's measured peer set (industry) also includes Sinocare (300298.SZ), PROCEPT BioRobotics (PRCT), El.En (ELN.MI), CONMED (CNMD), Shanghai MicroPort Endovascular MedTech (688016.SS), Nihon Kohden (6849.T).
Is Inner Mongolia Furui Medical Science expensive compared with its peers?
On forward p/e it trades at 41.9× against a peer median of 25.1×, 4th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -12 pp: the price already allows for a slowdown.
How has Inner Mongolia Furui Medical Science stock performed?
Over six months to 18 Nov 2026 the shares returned -31.5% against -1.8% for the median peer; over one year -45.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.